Lupin Receives Provisional FDA Approval for its Valbenazine Capsules
To market a generic version of Ingrezza® Capsules, 40 mg, 60 mg, and 80 mg of Neurocrine Biosciences, Inc., Lupin Limited (Lupin) today announced that its Abbreviated New Drug Application (ANDA), Valbenazine Capsules, 40 mg, 60 mg, and 80 mg, has received provisional approval from the United States Food and Drug Administration (U.S. FDA).